PRDM9 and acute lymphoblastic leukemia: We credential EHMT2/G9a, a SET domain-containing histone methyltransferase, as a potential therapeutic target in T-ALL and focus on elucidating and linking the role of G9a inhibitors as inducers of autophagic cell death.